Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression

被引:0
作者
H Wang
C Yan
I Asangani
H Allgayer
D D Boyd
机构
[1] MD Anderson Cancer Center,Department of Cancer Biology
[2] University of Heidelberg,Department of Experimental/Molecular Surgery
来源
Oncogene | 2007年 / 26卷
关键词
urokinase receptor; enhancer; gene expression;
D O I
暂无
中图分类号
学科分类号
摘要
The transcriptionally regulated urokinase-type plasminogen activator receptor (u-PAR) contributes to cancer progression. Although previous studies have identified multiple 5′ regulatory elements, these cis motifs cannot fully account for u-PAR expression prompting a search for hitherto uncharacterized regulatory elements. DNase I hypersensitivity and chromatin immunoprecipitation assays using u-PAR-expressing colon cancer cells indicated a hypersensitive region (+665/+2068) in intron 1 enriched with acetylated histone 3 (H3) and H3 methylated at lysine 4, markers of regulatory regions. The +665/+2068 region increased transcription from a u-PAR-promoter in an orientation- and distance-independent manner fulfilling the criteria of an enhancer. Optimal stimulation of the u-PAR promoter by phorbol ester required this enhancer. Systematic truncations combined with DNase I footprinting revealed two protected regions (+1060/+1099 and +1123/+1134) with deletion of the latter practically abolishing enhancer activity. The +1123/+1134 region harbored non-consensus activator protein-1 and Ets1 binding sites bound with c-Jun (and/or the related JunD/JunB) and c-Fos (and/or the related FosB/Fra-1/Fra-2) as revealed with chromatin immunoprecipitation. Further, nuclear extract from resected colon cancers showed elevated protein binding to a +1123/+1134-spanning probe coordinate with elevated u-PAR protein. Thus, we have defined a novel intragenic enhancer in the u-PAR gene required for constitutive and inducible expression.
引用
收藏
页码:2058 / 2070
页数:12
相关论文
共 323 条
  • [1] Aguirre-Ghiso JA(2001)Urokinase receptor and fibronectin regulate the ERK to p 38 Activity ratios that determine carcinoma cell proliferation or dormancy Mol Biol Cell 12 863-879
  • [2] Liu D(1998)Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a southwest oncology group study Cancer Res 58 1149-1158
  • [3] Mignatti A(1999)Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (−152/−135) bound with Sp1 J Biol Chem 274 18428-18445
  • [4] Kovalski K(1999)Targeted disruption of the K-Ras oncogene in invasive colon cancer downregulates urokinase receptor expression and plasminogene dependent proteolysis Br J Cancer 80 1884-1891
  • [5] Ossowski L(1999)Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2 J Biol Chem 274 4702-4714
  • [6] Ahnen DJ(2005)-related factor J Biol Chem 280 14811-14818
  • [7] Feigl P(1989)Regulation of urokinase receptor proteolytic function by the tetraspanin CD82 Cancer Res 49 4682-4689
  • [8] Quan G(1994) oncognees in human cancer: a review Blood 84 1151-1156
  • [9] Fenoglio-Preiser C(2005)The structure of the urokinase-type plasminogen activator receptor gene Biochem Biophys Res Commun 338 53-61
  • [10] Lovato LC(2004)An intronic enhancer regulates cyclooxygenase-1 gene expression J Biol Chem 279 11281-11292